Cargando…

Current Immunotherapeutic Approaches in Pancreatic Cancer

Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Koido, Shigeo, Homma, Sadamu, Takahara, Akitaka, Namiki, Yoshihisa, Tsukinaga, Shintaro, Mitobe, Jimi, Odahara, Shunichi, Yukawa, Toyokazu, Matsudaira, Hiroshi, Nagatsuma, Keisuke, Uchiyama, Kan, Satoh, Kenichi, Ito, Masaki, Komita, Hideo, Arakawa, Hiroshi, Ohkusa, Toshifumi, Gong, Jianlin, Tajiri, Hisao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172984/
https://www.ncbi.nlm.nih.gov/pubmed/21922022
http://dx.doi.org/10.1155/2011/267539
_version_ 1782211923503218688
author Koido, Shigeo
Homma, Sadamu
Takahara, Akitaka
Namiki, Yoshihisa
Tsukinaga, Shintaro
Mitobe, Jimi
Odahara, Shunichi
Yukawa, Toyokazu
Matsudaira, Hiroshi
Nagatsuma, Keisuke
Uchiyama, Kan
Satoh, Kenichi
Ito, Masaki
Komita, Hideo
Arakawa, Hiroshi
Ohkusa, Toshifumi
Gong, Jianlin
Tajiri, Hisao
author_facet Koido, Shigeo
Homma, Sadamu
Takahara, Akitaka
Namiki, Yoshihisa
Tsukinaga, Shintaro
Mitobe, Jimi
Odahara, Shunichi
Yukawa, Toyokazu
Matsudaira, Hiroshi
Nagatsuma, Keisuke
Uchiyama, Kan
Satoh, Kenichi
Ito, Masaki
Komita, Hideo
Arakawa, Hiroshi
Ohkusa, Toshifumi
Gong, Jianlin
Tajiri, Hisao
author_sort Koido, Shigeo
collection PubMed
description Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer.
format Online
Article
Text
id pubmed-3172984
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31729842011-09-15 Current Immunotherapeutic Approaches in Pancreatic Cancer Koido, Shigeo Homma, Sadamu Takahara, Akitaka Namiki, Yoshihisa Tsukinaga, Shintaro Mitobe, Jimi Odahara, Shunichi Yukawa, Toyokazu Matsudaira, Hiroshi Nagatsuma, Keisuke Uchiyama, Kan Satoh, Kenichi Ito, Masaki Komita, Hideo Arakawa, Hiroshi Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao Clin Dev Immunol Review Article Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer. Hindawi Publishing Corporation 2011 2011-09-14 /pmc/articles/PMC3172984/ /pubmed/21922022 http://dx.doi.org/10.1155/2011/267539 Text en Copyright © 2011 Shigeo Koido et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Koido, Shigeo
Homma, Sadamu
Takahara, Akitaka
Namiki, Yoshihisa
Tsukinaga, Shintaro
Mitobe, Jimi
Odahara, Shunichi
Yukawa, Toyokazu
Matsudaira, Hiroshi
Nagatsuma, Keisuke
Uchiyama, Kan
Satoh, Kenichi
Ito, Masaki
Komita, Hideo
Arakawa, Hiroshi
Ohkusa, Toshifumi
Gong, Jianlin
Tajiri, Hisao
Current Immunotherapeutic Approaches in Pancreatic Cancer
title Current Immunotherapeutic Approaches in Pancreatic Cancer
title_full Current Immunotherapeutic Approaches in Pancreatic Cancer
title_fullStr Current Immunotherapeutic Approaches in Pancreatic Cancer
title_full_unstemmed Current Immunotherapeutic Approaches in Pancreatic Cancer
title_short Current Immunotherapeutic Approaches in Pancreatic Cancer
title_sort current immunotherapeutic approaches in pancreatic cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172984/
https://www.ncbi.nlm.nih.gov/pubmed/21922022
http://dx.doi.org/10.1155/2011/267539
work_keys_str_mv AT koidoshigeo currentimmunotherapeuticapproachesinpancreaticcancer
AT hommasadamu currentimmunotherapeuticapproachesinpancreaticcancer
AT takaharaakitaka currentimmunotherapeuticapproachesinpancreaticcancer
AT namikiyoshihisa currentimmunotherapeuticapproachesinpancreaticcancer
AT tsukinagashintaro currentimmunotherapeuticapproachesinpancreaticcancer
AT mitobejimi currentimmunotherapeuticapproachesinpancreaticcancer
AT odaharashunichi currentimmunotherapeuticapproachesinpancreaticcancer
AT yukawatoyokazu currentimmunotherapeuticapproachesinpancreaticcancer
AT matsudairahiroshi currentimmunotherapeuticapproachesinpancreaticcancer
AT nagatsumakeisuke currentimmunotherapeuticapproachesinpancreaticcancer
AT uchiyamakan currentimmunotherapeuticapproachesinpancreaticcancer
AT satohkenichi currentimmunotherapeuticapproachesinpancreaticcancer
AT itomasaki currentimmunotherapeuticapproachesinpancreaticcancer
AT komitahideo currentimmunotherapeuticapproachesinpancreaticcancer
AT arakawahiroshi currentimmunotherapeuticapproachesinpancreaticcancer
AT ohkusatoshifumi currentimmunotherapeuticapproachesinpancreaticcancer
AT gongjianlin currentimmunotherapeuticapproachesinpancreaticcancer
AT tajirihisao currentimmunotherapeuticapproachesinpancreaticcancer